Distribution and Drug Resistance of Pathogenic Bacteria and Prognosis in Patients with Septicemia Bloodstream Infection with Renal Insufficiency

Figures & data

Table 1 Comparison of General Information of Each Group

Item	Study group (112)	Control Group (112)	t/χ^2	P
Age (years)	54.92±11.56	54.78±11.46	0.091	0.928
Gender (male/female)	61/51	63/49	0.072	0.788
BMI (kg/m2)	24.78±3.49	24.83±3.53	−0.107	0.915
Disease severity
Sequential organ failure score (points)	5.63±1.02	5.43±1.09	1.418	0.158
Acute physiological and chronic health score (points)	22.18±2.34	22.09±2.29	0.291	0.771
Disseminated intravascular coagulation score (points)	3.11±0.78	3.06±0.83	0.465	0.642
Infection causation (n)
Surgical	67(59.82)	69(61.61)	0.075	0.784
Internal medicine	45(40.18)	43(38.39)	0.075	0.784
Diabetes mellitus (n)	37(33.04)	35(31.25)	0.082	0.775
Chronic obstructive pulmonary disease (n)	20(17.86)	22(19.64)	0.117	0.732
Impaired consciousness (n)	52(46.43)	54(48.21)	0.996	0.072
Hepatic insufficiency (n)	16(14.28)	13(11.61)	0.356	0.551
Invasive operations (n)	51(45.54)	48(42.86)	0.163	0.686
Preventive use of antimicrobial drugs (n)	78(69.64)	75(66.96)	0.186	0.666

Table 2 Comparison of the Distribution of Drug-Resistant Bacteria Between the Two Groups n (%)

Pathogenic Bacteria n (%)	Study Group (140)	Control Group (136)	χ^2	P
Gram-negative bacteria	71(50.71%)	93(68.38%)	11.018	0.001
Klebsiella pneumoniae	29(20.71%)	38(27.94%)
Escherichia coli	8(5.71%)	20(14.71%)
Acinetobacter baumannii	16(14.29%)	26(19.12%)
Pseudomonas aeruginosa	6(4.29%)	6(4.41%)
Other	2(1.43%)	3(2.21%)
Gram-positive bacteria	57(40.71%)	36(32.14%)	8.108	0.004
Staphylococcus epidermidis	6(4.29%)	4(2.94%)
Glucococcus aureus	11(7.86%)	9(6.62%)
Enterococcus	16(11.43%)	10(7.35%)
Listeria monocytogenes	4(2.86%)	2(1.47%)
Pneumococcus spp.	6(4.29%)	3(2.21%)
Streptococcus pneumoniae	10(7.14%)	4(2.94%)
Other	4(2.86%)	4(2.94%)
Fungi	12(8.57%)	7(5.15%)	1.438	0.230
Pseudomonas albicans	3(2.14%)	2(1.47%)
Aspergillus	6(4.29%)	3(2.21%)
Other	3(2.14%)	2(1.47%)

Table 3 Drug Resistance in Common Gram-Negative Bacteria n (%)

Pathogenic Bacteria	Klebsiella pneumoniae(67)	Escherichia coli(28)	Pseudomonas aeruginosa(12)	Acinetobacter baumannii(42)
Tigecycline	5(7.46)	3(10.71)	–	9(21.43)
Amikacin	30(44.78)	13(46.43)	6(50.00)	22(52.38)
Levofloxacin	38(56.72)	16(57.14)	8(66.67)	31(73.81)
Imipenem	25(37.31)	10(35.71)	5(41.67)	27(64.29)
Cefoperazone	29(43.28)	10(35.71)	7(58.33)	24(57.14)
Ceftriaxone	42(62.69)	15(53.57)	–	–
Ceftazidime	38(56.72)	16(57.14)	7(58.33)	34(80.95)
Piperacillin	34(50.75)	15(53.57)	6(50.00)	30(71.43)
Amoxicillin	7(10.45)	3(10.71)	–	13(30.95)
Minocycline	9(13.43)	6(21.43)	–	–

Table 4 Drug Resistance of Common Gram-Positive Bacteria n (%)

Pathogenic Bacteria	Streptococcus pneumoniae(14)	Enterococcus(26)	Staphylococcus aureus(20)
Linezolid	0	0	0
Vancomycin	0	2(7.69%)	0
Gentamicin	9(64.29%)	12(46.15%)	12(60.00%)
Compound sulfamethoxazole	6(42.86%)	–	7(35.00%)
Rifampicin	6(42.86%)	–	8(40.00%)
Levofloxacin	8(57.14%)	14(53.85%)	11(55.00%)
Clindamycin	10(71.43%)	24(92.31%)	15(75.00%)
Azithromycin	9(64.29%)	23(88.46%)	15(75.00%)
Cefazolin	10(71.43%)	17(65.38%)	14(70.00%)
Penicillin G	8(66.67%)	21(18.75%)	17(85.00%)

Table 5 Comparison of Multi-Drug Resistant Bacterial Infections Between the Two Groups

Pathogenic Bacteria n(%)	Study Group(112)	Control Group(112)	χ^2	P
MDR-AB	7(6.25%)	5(4.46%)	0.352	0.553
MDR-PA	9(8.04%)	4(3.57%)	2.042	0.153
ESBLs	38(33.93%)	24(21.43%)	4.371	0.366
VRE	0	2(1.79%)	2.018	0.155
MRSA	10(8.93%)	7(6.25%)	0.573	0.449

Abbreviations: MDR-AB, multi-drug resistant Acinetobacter baumannii; MDR-PA, multi-drug resistant Pseudomonas aeruginosa; extended spectrum β-lactamase producing Enterobacteriaceae; VRE, vancomycin-resistant enterococci; MRSA, methicillin-resistant Staphylococcus aureus.

Table 6 Comparison of the Efficacy of the Two Groups n (%)

Indicator	Study Group(112)	Control Group(112)	χ^2	P
Apparent effect	12(10.71%)	16(14.29%)
Effective	4(3.57%)	5(1.79%)
Ineffective	96(85.71%)	91(81.25%)
Total effective rate n (%)	16(14.29%)	21(18.75%)	0.809	0.368

Table 7 Comparison of the Incidence of Septic Shock, Duration of Mechanical Ventilation, Length of Hospital Stay, and Duration of Antimicrobial Drug Administration Between the Two Groups ()

Indicator	Study Group(112)	Control Group(112)	x^2/t	P
Incidence of septic shock (n)	10(8.93%)	7(6.25%)	0.573	0.449
Duration of mechanical ventilation (d)	11.37±2.39	10.83±2.76	1.565	0.119
Length of hospitalization (d)	21.78±4.01	18.49±3.91	6.217	<0.001
Duration of antimicrobial drug administration (d)	18.93±3.37	15.03±3.02	9.121	<0.001